Chronic Kidney Disease – Pipeline Review, H1 2017; New Report Launched

Leadership is an overused word, and is often misused. We like this definition.

DrugPipeline.net has announced the addition of “Chronic Kidney Disease – Pipeline Review, H1 2017” research report to their website www.DrugPipeline.net

Bangalore, India — (SBWIRE) — 05/19/2017 — Pharmaceutical and Healthcare disease pipeline guide Chronic Kidney Disease – Pipeline Review, H1 2017, provides an overview of the Chronic Kidney Disease (Genito Urinary System And Sex Hormones) pipeline landscape.

Chronic kidney disease is the slow loss of kidney function over time. Signs and symptoms of kidney disease include nausea, vomiting, loss of appetite, fatigue and weakness, sleep problems, hiccups and swelling of feet and ankles. The predisposing factors include age, diabetes, high blood pressure, heart disease, smoking, obesity and high cholesterol.

Report Highlights

Pharmaceutical and Healthcare latest pipeline guide Chronic Kidney Disease – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chronic Kidney Disease (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Kidney Disease (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 10, 18, 1, 20 and 5 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.

Chronic Kidney Disease (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Kidney Disease (Genito Urinary System And Sex Hormones).
– The pipeline guide reviews pipeline therapeutics for Chronic Kidney Disease (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Chronic Kidney Disease (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Chronic Kidney Disease (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Kidney Disease (Genito Urinary System And Sex Hormones)

Reasons to buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Chronic Kidney Disease (Genito Urinary System And Sex Hormones).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Chronic Kidney Disease (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Spanning over 195 pages "Chronic Kidney Disease – Pipeline Review, H1 2017" report covers Introduction, Chronic Kidney Disease (Chronic Renal Failure) – Overview, Chronic Kidney Disease (Chronic Renal Failure) – Therapeutics Development, Pipeline Overview, Appendix, Methodology. The report covered companies are – Angion Biomedica Corp, apceth Biopharma GmbH, Astellas Pharma Inc, AstraZeneca Plc, Bayer AG, BLR Bio LLC, Boehringer Ingelheim GmbH, Boryung Pharmaceutical Co Ltd, Cellmid Ltd, Chugai Pharmaceutical Co Ltd

For more information Visit at: http://www.drugpipeline.net/global-markets-direct/chronic-kidney-disease-pipeline-review-h1-2017

Find all Diseases Reports at – http://www.drugpipeline.net/catalog/diseases

About DrugPipeline.net
DrugPipeline.net is a market research reports distribution platform which hosts research reports from all leading global market research firms related to pharma industry. It also assist decision makers locate the right market research solution from a single place.

For more information on this press release visit: http://www.sbwire.com/press-releases/chronic-kidney-disease-pipeline-review-h1-2017-new-report-launched-809142.htm

Media Relations Contact

Sudeep Chakravarty
Director – Operations
DrugPipeline.net
Telephone: 302-703-9904
Email: Click to Email Sudeep Chakravarty
Web: http://www.drugpipeline.net/global-markets-direct/chronic-kidney-disease-pipeline-review-h1-2017